Neurological adverse events of blinatumomab in children with B-cell acute lymphoblastic leukemia: a retrospective study Authors: Yuan-Yuan Zeng, Yong Zhang, Feng Chen, Yong-Jun Fang Published: 2026 ABSTRACT ObjectiveThis study aims to conduct a real-world analysis of blinatumomab-associated neurological adverse events (NAEs) in pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL) to comprehensively elucidate its safety profile.MethodsA retrospective analysis was conducted in children with B-ALL who were treated at hematology medical ward of our institution from January 2024 to December 2025. Document the occurrence of all NAEs during the dosing cycle of blinatumomab, including the time of occurrence, cycle of appearance, severity, management, and outcome.ResultsThere were 13 individuals with an average age of 10.08 ± 4.23 years experienced a total of 18 NAEs among all the 60 B-ALL patients. These NAEs primarily manifest as headache, dizziness, tremor, delirium, status epilepticus, and cerebral herniation. Most NAEs occur during the first cycle of medication (77.78%). The median onset time of the NAEs was approximately 9.5 days, with a duration of approximately 2.78 ± 2.21 days. The majority of NAEs associated with blinatumomab are mild to moderate in severity (grade 1 or 2) (88.89%). Two patients experienced severe adverse events (AEs) (grade 4), manifesting as status epilepticus and cerebral herniation. There were statistically significant differences in age (10.08 ± 4.23 vs. 5.40 ± 3.57; P < 0.01), and the proportion of males (84.62% vs. 55.32%; P = 0.03) between the group with NAEs and without. Additionally, we found age was identified as an independent predictor of blinatumomab-associated NAEs.ConclusionThis study reveals real-world data on the neurological safety profile of blinatumomab, characterizes the features of it, and identifies age as an independent predictor of blinatumomab-associated NAEs in pediatric patients.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12887-026-07118-5. Introduction Acute lymphoblastic leukemia (ALL) is the most prevalent malignant disease in pediatric populations, accounting for approximately 25% of childhood cancers worldwide [1]. Among ALL subtypes, B-cell acute lymphoblastic leukemia (B-ALL) represents the predominant form, comprising 75–80% of pediatric cases. Despite advances in treatment protocols, relapse remains a critical challenge, contributing to 15–20% of treatment failures in pediatric B-ALL [2]. Minimal residual disease (MRD) is a significant risk factor for relapse [3]. Reduction or interruption of chemotherapy intensity due to treatment intolerance or complications may also increase the risk of recurrence. Thus, more effective treatments are needed for relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) among children. Blinatumomab is a bispecific T-cell engager (BiTE) targeting CD19 and CD3, which redirects CD3 + T cells to specifically recognize and eliminate CD19 + tumor cells. It has demonstrated favorable efficacy in the treatment of R/R B-ALL, eradication of MRD, and maintenance therapy in patients with chemotherapy intolerance [4–7]. Although blinatumomab is generally well tolerated, severe AEs such as cytokine release syndrome (CRS), neurotoxicity, and infections have been observed in clinical trials and real-world studies, which may lead to treatment discontinuation [8–11]. Neurological adverse event (NAE) is a frequent and serious AE associated with blinatumomab [12, 13]. Due to the inherent constraints of clinical trials—including restricted enrollment of specific patient populations, relatively small sample sizes, limited follow-up periods, and stringent inclusion/exclusion criteria—the potential association between blinatumomab and NAE remains ambiguous. Therefore, continuous post-marketing surveillance of blinatumomab is essential to further clarify its safety profile regarding neurotoxicity. Thus, this study aims to perform a real-world analysis of blinatumomab-associated NAEs in pediatric patients with B-ALL to comprehensively elucidate its safety profile. Such efforts will facilitate evidence-based clinical decision-making and promote rational drug utilization in pediatric oncology. Methods This study was approved by the Children’s Hospital of Nanjing Medical University Research Ethics Committee (202602037-1). The need for informed consent was waived. Patients A retrospective analysis was conducted on children diagnosed with B-ALL who received blinatumomab treatment at the hematology medical ward of our institution between January 2024 and December 2025. Patients aged 1 month to 18 years who received at least one cycle of blinatumomab were eligible. All children were divided into two groups: those with NAEs and those without. Blinatumomab treatment protocol Blinatumomab is currently used in our institution for the following indications: (1) R/R B-ALL; (2) B-ALL with positive minimal residual disease (MRD); (3) unable to tolerate chemotherapy; and (4) in accordance with the institutional treatment protocol, Chinese Children’s Cancer Group-2025 Protocol for Newly Diagnosed Childhood B-cell Acute Lymphoblastic Leukemia (CCCG-B-ALL-2025) (Pediatric patients with B-ALL received a standard 28-day course of blinatumomab therapy following induction remission treatment.). All patients included in this study received intrathecal chemotherapy one day prior to the initiation of blinatumomab as prophylaxis against central nervous system involvement of B-ALL. For patients with body weight ≥ 45 kg, a fixed-dose regimen of blinatumomab was administered: 9 µg /day intravenously on days 1–7, followed by 28 µg/day on days 8–28. Patients weighing < 45 kg received a body surface area (BSA)-based dose: 5 µg/m²/day (maximum 9 µg/day) on days 1–7, and 15 µg/m²/day (maximum 28 µg/day) on days 8–28. All infusions were delivered via continuous intravenous infusion over 24 h. All patients received dexamethasone (5mg/m2) on the first day of blinatumomab treatment and on the first day of dose escalation (day 8 of therapy). Cytokine testing was not protocol-mandated but physician-dependent. The graded management strategy for blinatumomab-associated NAEs, based on the FDA prescribing information for blinatumomab [14] is detailed in Supplementary Table 1. Data collection Record all NAEs throughout the blinatumomab dosing cycle, documenting the timing, cycle of onset, severity, management measures, and patient outcomes. The severity of adverse drug reactions (ADRs) should be graded according to the Common Terminology Criteria for Adverse Events, version 6.0 (CTCAE v6.0). We reviewed the medical records of B-ALL patients, collecting demographic data (e.g., age, body weight and sex) and laboratory parameters, including white blood cell count (WBC), absolute neutrophil count (ANC), platelet count (PLT), alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB), serum creatinine (Scr), interleukin (IL)-6, tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), and IL-10. All laboratory indicators (WBC, ANC, PLT, ALT, AST, ALB, and Scr) were measured before the initiation of blinatumomab therapy. Cytokine levels (IL-6, TNF-α, IFN-γ, and IL-10) were assessed after blinatumomab administration. Statistical analyses SPSS Statistics version 26.0 was used for statistical analyses. Categorical variables were summarized using frequencies (%). Continuous variables were expressed as mean ± SD for normally distributed data or median (IQR) for non-normally distributed data. Shapiro-Wilk test was used to examine whether the data were normally distributed. We used the χ2 test to compare categorical data. The independent samples t-test was used to compare groups of normally distributed data, and the Mann–Whitney U test was used for non-normally distributed data. Multivariate analysis was conducted using binary logistic regression analysis. Statistical significance was set at P < 0.05. Results Baseline characteristics Between January 2024 and December 2025, 60 pediatric patients with an average age of 6.41 ± 4.19 years diagnosed with B-ALL received a total of 99 treatment cycles with blinatumomab in the hematology ward of our insititution. None of the patients had Down syndrome, and no patient experienced neurotoxicity following an unplanned interruption and subsequent resumption of blinatumomab, nor did any patient in this study receive antiepileptic prophylaxis. Cytokine testing were measured in 30 patients (50%). The demographic and clinical characteristics of these patients are shown in Table 1. Among these patients, 13 individuals experienced a total of 18 NAEs. There were significant differences between the NAE and non-NAE groups in age (10.08 ± 4.23 vs. 5.40 ± 3.57; P < 0.01) and the proportion of male patients (84.62% vs. 55.32%; P = 0.03). However, no significant differences were observed between the two groups regarding the proportion of patients with MRD status prior to treatment, the proportion of patients with relapsed or refractory disease, or the incidence of CRS. Table 1Demographic and clinical features of NAE patients and non-NAE patientsTotal (n = 60)NAE patients (n = 13)Non-NAE patients (n = 47)P valueAge, y, (mean ± SD)6.41 ± 4.1910.08 ± 4.235.40 ± 3.57< 0.01Male, n (%)37 (61.67)11 (84.62)26 (55.32)0.03MRD negative before treatment, n (%)49 (81.67)12 (92.31)37 (78.72)0.18Relapsed and refractory cases, n (%)35 (58.33)10 (76.92)25 (53.19)0.24CRS, n (%)8 (13.33)3 (23.08)5 (10.64)0.12BSA body surface area, CRS Cytokine Release Syndrome, MRD minimal residual disease, MRD negative MRD<0.01%, NAE neurological adverse events Table 1Demographic and clinical features of NAE patients and non-NAE patientsTotal (n = 60)NAE patients (n = 13)Non-NAE patients (n = 47)P valueAge, y, (mean ± SD)6.41 ± 4.1910.08 ± 4.235.40 ± 3.57< 0.01Male, n (%)37 (61.67)11 (84.62)26 (55.32)0.03MRD negative before treatment, n (%)49 (81.67)12 (92.31)37 (78.72)0.18Relapsed and refractory cases, n (%)35 (58.33)10 (76.92)25 (53.19)0.24CRS, n (%)8 (13.33)3 (23.08)5 (10.64)0.12BSA body surface area, CRS Cytokine Release Syndrome, MRD minimal residual disease, MRD negative MRD<0.01%, NAE neurological adverse events Demographic and clinical features of NAE patients and non-NAE patients BSA body surface area, CRS Cytokine Release Syndrome, MRD minimal residual disease, MRD negative MRD<0.01%, NAE neurological adverse events Summary of information on NAEs caused by blinatumomab There were 13 individuals with an average age of 10.08 ± 4.23 years experienced a total of 18 NAEs among all the 60 B-ALL patients. These NAEs primarily manifest as headache, dizziness, tremor, delirium, status epilepticus, and cerebral herniation. Most NAEs occur during the first cycle of medication (77.78%). The median onset time of the NAEs was approximately 9.5 days, with a duration of approximately 2.78 ± 2.21 days. The majority of NAEs associated with blinatumomab are mild to moderate in severity (grade 1 or 2) (88.89%). All patients who had grade 1 and 2 NAE were able to resume and complete their course of blinatumomab. Two patients experienced grade 4 NAEs during the second cycle of medication, both of whom were status epilepticus, and one of them also experienced cerebral herniation. The summary of information on NAEs caused by blinatumomab were listed in Table 2. Management of blinatumomab-associated NAEs were guided by a graded strategy based on symptom severity. Grade 1 events were managed by either reducing the infusion rate or continuing the infusion with close monitoring; Grade ≥ 2 events prompted temporary interruption or permanent discontinuation of blinatumomab, in combination with dexamethasone therapy; Mannitol was reserved for cases with suspected cerebral edema or intracranial hypertension (detailed protocol provided in Supplementary Table 1). Table 2Summary of information on NAE caused by blinatumomabCaseAgeAccompanying diseases/symptomsNAEsCycle NumberOnset Time/dDuration/dManagementAdverse Reaction Grade of NAE123415nausea; vomit; CRSdizziness121suspend infusion of blinatumomab;intravenous infusion of mannitol√headache1121suspend infusion of blinatumomab;intravenous infusion of mannitol√210CRSheadache226suspend infusion of blinatumomab;intravenous infusion of dexamethasone√33headache121suspend infusion of blinatumomab;intravenous infusion of dexamethasone√headache184self relieving√413CRS; hypertensionheadache2123suspend infusion of blinatumomab;intravenous infusion of dexamethasone and mannitol√status epilepticus2165discontinue use of blinatumomab;intravenous infusion of dexamethasone, diazepam and mannitol√5*13feverdelirium; status epilepticus; brain herniation2139discontinue use of blinatumomab;intravenous infusion of dexamethasone, diazepam and mannitol; various rescue measures#√67transient dizzinessdizziness1131monitoring vital signs√transient limb tremorslimb tremors1231timely observation√78transient deliriumdelirium141timely observation√88transient dizzinessdizziness131timely observation√98hand tremor1114intravenous infusion of mecobalamin√1014tremor1174reduce the infusion speed of blinatumomab; intravenous infusion of dexamethasone and mecobalamin√1116headache132suspend infusion of blinatumomab; intravenous infusion of dexamethasone√1218headache122suspend infusion of blinatumomab; intravenous infusion of dexamethasone√138tremor132suspend infusion of blinatumomab; intravenous infusion of dexamethasone√fevertremor1172suspend infusion of blinatumomab; intravenous infusion of dexamethasone√CRS cytokine release syndrome, NAE neurological adverse events*: Patient 5’s parents requested to be discharged, so we have not been able to track the patient’s follow-up#: various rescue measures such as electrocardiogram (ECG)/electroencephalography (EEG) monitoring, mechanical ventilation, volume expansion with normal saline and intravenous push of epinephrine Table 2Summary of information on NAE caused by blinatumomabCaseAgeAccompanying diseases/symptomsNAEsCycle NumberOnset Time/dDuration/dManagementAdverse Reaction Grade of NAE123415nausea; vomit; CRSdizziness121suspend infusion of blinatumomab;intravenous infusion of mannitol√headache1121suspend infusion of blinatumomab;intravenous infusion of mannitol√210CRSheadache226suspend infusion of blinatumomab;intravenous infusion of dexamethasone√33headache121suspend infusion of blinatumomab;intravenous infusion of dexamethasone√headache184self relieving√413CRS; hypertensionheadache2123suspend infusion of blinatumomab;intravenous infusion of dexamethasone and mannitol√status epilepticus2165discontinue use of blinatumomab;intravenous infusion of dexamethasone, diazepam and mannitol√5*13feverdelirium; status epilepticus; brain herniation2139discontinue use of blinatumomab;intravenous infusion of dexamethasone, diazepam and mannitol; various rescue measures#√67transient dizzinessdizziness1131monitoring vital signs√transient limb tremorslimb tremors1231timely observation√78transient deliriumdelirium141timely observation√88transient dizzinessdizziness131timely observation√98hand tremor1114intravenous infusion of mecobalamin√1014tremor1174reduce the infusion speed of blinatumomab; intravenous infusion of dexamethasone and mecobalamin√1116headache132suspend infusion of blinatumomab; intravenous infusion of dexamethasone√1218headache122suspend infusion of blinatumomab; intravenous infusion of dexamethasone√138tremor132suspend infusion of blinatumomab; intravenous infusion of dexamethasone√fevertremor1172suspend infusion of blinatumomab; intravenous infusion of dexamethasone√CRS cytokine release syndrome, NAE neurological adverse events*: Patient 5’s parents requested to be discharged, so we have not been able to track the patient’s follow-up#: various rescue measures such as electrocardiogram (ECG)/electroencephalography (EEG) monitoring, mechanical ventilation, volume expansion with normal saline and intravenous push of epinephrine Summary of information on NAE caused by blinatumomab suspend infusion of blinatumomab; intravenous infusion of mannitol suspend infusion of blinatumomab; intravenous infusion of mannitol suspend infusion of blinatumomab; intravenous infusion of dexamethasone suspend infusion of blinatumomab; intravenous infusion of dexamethasone suspend infusion of blinatumomab; intravenous infusion of dexamethasone and mannitol discontinue use of blinatumomab; intravenous infusion of dexamethasone, diazepam and mannitol discontinue use of blinatumomab; intravenous infusion of dexamethasone, diazepam and mannitol; various rescue measures# CRS cytokine release syndrome, NAE neurological adverse events *: Patient 5’s parents requested to be discharged, so we have not been able to track the patient’s follow-up #: various rescue measures such as electrocardiogram (ECG)/electroencephalography (EEG) monitoring, mechanical ventilation, volume expansion with normal saline and intravenous push of epinephrine Risk factors for blinatumomab‑associated NAEs Multivariate logistic regression analysis revealed that age is an independent predictor of NAEs associated with blinatumomab. Among pediatric patients, older age is linked to a higher risk of developing NAEs (Table 3). Table 3Univariate and multivariate analysis of NAE induced by blinatumomabVariableUnivariateMultivariateOR(95%CI)P valueβS.EWaldχ2P valueExp(B)Treatment cycle0.44(0.14–1.34)0.15R/R cases0.31(0.08–1.22)0.10Gender0.27(0.06–1.27)0.10Age1.32(1.12–1.56)0.0010.300.125.890.0151.34MRD negative before treatment0.51(0.06–4.32)0.54WBC0.96(0.80–1.16)0.69ANC0.95(0.74–1.23)0.71PLT1.00(0.99-1.00)0.32ALT1.00(0.99–1.01)0.80AST0.99(0.97–1.01)0.53ALB0.97(0.87–1.09)0.65Scr1.08(1.02–1.15)0.011-0.110.050.060.810.99IL-61.00(0.81–1.23)0.97TNF-α0.81(0.59–1.12)0.20IFN- γ0.91(0.78–1.08)0.27IL-100.90(0.66–1.21)0.48ALB albumin, ALT alanine aminotransferase, AST aspartate aminotransferase, IFN-γ interferon-gamma, IL-6 interleukin-6, IL-10 interleukin-10, MRD minimal residual disease, MRD negative MRD<0.01%, PLT platelet count, R/R cases relapsed or refractory cases, Scr serum creatinine, TNF-α tumor necrosis factor α, WBC white blood cell Table 3Univariate and multivariate analysis of NAE induced by blinatumomabVariableUnivariateMultivariateOR(95%CI)P valueβS.EWaldχ2P valueExp(B)Treatment cycle0.44(0.14–1.34)0.15R/R cases0.31(0.08–1.22)0.10Gender0.27(0.06–1.27)0.10Age1.32(1.12–1.56)0.0010.300.125.890.0151.34MRD negative before treatment0.51(0.06–4.32)0.54WBC0.96(0.80–1.16)0.69ANC0.95(0.74–1.23)0.71PLT1.00(0.99-1.00)0.32ALT1.00(0.99–1.01)0.80AST0.99(0.97–1.01)0.53ALB0.97(0.87–1.09)0.65Scr1.08(1.02–1.15)0.011-0.110.050.060.810.99IL-61.00(0.81–1.23)0.97TNF-α0.81(0.59–1.12)0.20IFN- γ0.91(0.78–1.08)0.27IL-100.90(0.66–1.21)0.48ALB albumin, ALT alanine aminotransferase, AST aspartate aminotransferase, IFN-γ interferon-gamma, IL-6 interleukin-6, IL-10 interleukin-10, MRD minimal residual disease, MRD negative MRD<0.01%, PLT platelet count, R/R cases relapsed or refractory cases, Scr serum creatinine, TNF-α tumor necrosis factor α, WBC white blood cell Univariate and multivariate analysis of NAE induced by blinatumomab ALB albumin, ALT alanine aminotransferase, AST aspartate aminotransferase, IFN-γ interferon-gamma, IL-6 interleukin-6, IL-10 interleukin-10, MRD minimal residual disease, MRD negative MRD<0.01%, PLT platelet count, R/R cases relapsed or refractory cases, Scr serum creatinine, TNF-α tumor necrosis factor α, WBC white blood cell Discussion To the best of our knowledge, this study first represents the real-world characterization of the features, onset time, duration, managements and severity of NAEs associated with blinatumomab in pediatric patients. Blinatumomab is a bispecific CD19-directed CD3 T-cell engager. Although blinatumomab demonstrates overall favorable tolerability, its safety profile in pediatric populations still requires special attention. In an international prospective clinical trial [15], approximately 73.6% of pediatric patients experienced varying degrees of blinatumomab-related AEs, with 26.4% classified as serious AEs (≥ grade 3). Additionally, 16.0% of patients necessitated temporary discontinuation of blinatumomab due to AEs, while 4.0% discontinued treatment permanently as a result of AE-related complications. Neurotoxicity associated with blinatumomab is one of the most common reasons for treatment discontinuation [16, 17]. The American Society for Transplantation and Cellular Therapy (ASTCT) classifies the neurotoxicity that occurs during CRS as immune effector cell associated neurotoxicity syndrome (ICANS) [18]. ICANS is a specific type of NAE, typically associated with immunotherapies such as CAR-T cell therapy or bispecific antibodies like blinatumomab, and is considered a subset of NAEs. ICANS has not yet been fully elucidated in terms of its exact pathological mechanisms. Currently, it is believed that its pathogenesis involves the following processes: endothelial cell activation leading to coagulation imbalance, deposition of basement membrane collagen triggering microvascular structural remodeling, increased capillary permeability causing protein leakage, T-lymphocyte infiltration in the cerebrospinal fluid along with elevated levels of pro-inflammatory mediators, and blood-brain barrier disruption contributing to the entry of neurotoxic substances into the brain [19]. Although ICANS is often secondary to CRS, not all severe CRS patients develop ICANS, nor do all ICANS patients exhibit CRS symptoms. Our study confirmed that there was no relationship between the occurrence of CRS and NAEs (P = 0.12). In clinical trials, the incidence of NAEs related to blinatumomab in the pediatric population ranges from 15% to 48%, and most cases occur during the first cycle of treatment [7, 8, 20]. Our study revealed that 22% of pediatric patients encountered NAEs, most of which were observed in the initial treatment cycle, aligning with results from earlier studies. Blinatumomab-related NAEs are commonly manifested as headache and tremor. However, a small subset of patients may experience severe or life-threatening AEs, such as encephalopathy, seizures, speech and consciousness disorders, confusion, and disorientation [21]. In our study, the majority of blinatumomab-associated NAEs were mild to moderate in severity (grade 1 or 2) (88.89%), and manifested as headache, dizziness and tremor. Our study observed that two patients encountered severe NAE during the second cycle of treatment, with both patients exhibiting status epilepticus, and one patient additionally experiencing cerebral herniation. Even after the first treatment cycle, severe neurotoxicity may still occur, underscoring the importance of continued vigilance. In a phase 2 study [22], the median onset time of blinatumomab-related NAEs is 9 days with median duration of 5 days in adults. Our study revealed that blinatumomab-related NAEs in pediatric patients had a median time to onset of 9.5 days, which is similar to the data observed in adults. However, blinatumomab-related NAEs have a median duration of 2 days in pediatric patients, significantly shorter than the 5-day duration observed in adults. Blinatumomab exhibits a very short elimination half-life [23], with most adverse effects resolving upon discontinuation of infusion and initiation of corticosteroid therapy. In our study, patients who developed NAEs showed clinical improvement within a median of 2 days following individualized interventions, which included reduced infusion rate, temporary drug discontinuation, or dexamethasone administration, alone or in combination. In recent years, researchers have begun to pay attention to the risk factors of blinatumomab-related NAEs, predominantly in adult patients [13, 22]. Anthony and his colleagues [22] found that NAEs were more frequent in patients ≥ 65 years than < 65 years (72% vs. 49%). While another study based on the FAERS database found that those aged between 18 and 45 years had the highest number of reported cases of NAEs, and patients under 18 years of age had the highest number of reported cases of fatal NAEs. The results of this study indicate that the incidence of blinatumomab-related NAEs is higher in older children (10.08 ± 4.23 years old) compared to younger ones (5.40 ± 3.57 years old). Furthermore, multivariate logistic regression analysis demonstrates that age is an independent predictor of NAEs in pediatric patients, and this is confirmed by previous study [13]. Men have a higher probability of experiencing NAEs than women in our study, and this is consistent with the data from the FAERS database [13]. This phenomenon may be closely related to the higher incidence of ALL in males [2]. Blinatumomab binds to CD19 on the surface of B cells and CD3 on the surface of T cells to form immune synapses, thereby promoting cytokine release such as IL-2, TNF-α, IFN-γ, IL-6, and IL-10. In approximately half of the patients, a transient elevation of cytokines such as IL-6, IL-10, and TNF-α was observed within 2 days of blinatumomab infusion, peaking and subsequently returning to baseline within 24–48 h [24, 25]. Research has shown that the peak level of IL-6 is correlated with the severity of CRS [26]. Patients with severe ICANS also observed elevated levels of IL-6 and IFN-γ [27]. However, it has not been confirmed that the peak level of cytokines is associated with the occurrence of blinatumomab-related NAEs. In our multivariate analysis, cytokines such as IL-6, IL-10, TNF-α and IFN-γ were not independent predictors of NAEs in pediatric patients. Another multivariate analysis on adult patients [22] showed that race other than white and prior neurologic events were risk factors for blinatumomab-related NAEs. Our study only included Asian populations and excluded individuals with pre-existing central nervous system abnormalities at the beginning of the study. Limitations This article has several limitations. First, no patients in our cohort had documented pre-existing renal or hepatic insufficiency, baseline central nervous system abnormalities, or received concurrent immunotherapy at the time of blinatumomab administration. The absence of these potentially higher-risk subgroups introduces selection bias, thereby limiting the generalizability of our findings as a real-world report. Consequently, collaborative, multi-center studies are needed to enroll sufficient numbers of such patients to adequately evaluate the safety and efficacy of blinatumomab in these populations. Second, cytokine measurements were not routinely performed but were obtained at the discretion of the treating physicians, typically in patients who developed clinically overt CRS (Supplementary Table 2). Therefore, our cytokine findings should be considered hypothesis-generating rather than definitive. Third, Our study was limited by the relatively low incidence and mild severity of CRS in this pediatric cohort. All CRS events were grade 1–2, which precluded a stratified analysis examining the association between severe (grade 3–4) CRS and neurotoxicity. Larger multi-center studies with sufficient power to capture severe CRS events are warranted to address this important question. Conclusion In conclusion, this study provides real-world data on the neurological safety profile of blinatumomab, characterizes its key features, and identifies age as an independent predictor of blinatumomab-associated NAEs in pediatric patients. Supplementary Information Supplementary Material 1: Table S1 Graded Management Strategy for Blinatumomab-Associated NAEs. Table S2 Demographic and clinical features of patients had cytokine data (A) and those without (B). Supplementary Material 1: Table S1 Graded Management Strategy for Blinatumomab-Associated NAEs. Table S2 Demographic and clinical features of patients had cytokine data (A) and those without (B).